[HTML][HTML] Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

PC Fong, DS Boss, TA Yap, A Tutt, P Wu… - … England Journal of …, 2009 - Mass Medical Soc
Background The inhibition of poly (adenosine diphosphate [ADP]–ribose) polymerase
(PARP) is a potential synthetic lethal therapeutic strategy for the treatment of cancers with …

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled …

RL Coleman, AM Oza, D Lorusso, C Aghajanian… - The Lancet, 2017 - thelancet.com
Background Rucaparib, a poly (ADP-ribose) polymerase inhibitor, has anticancer activity in
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome …

[PDF][PDF] Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

PC Fong, TA Yap, DS Boss, CP Carden… - Journal of clinical …, 2010 - researchgate.net
Purpose Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy
using poly (ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers …

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors

I Ray-Coquard, J Brown, P Harter… - International Journal of …, 2014 - ijgc.bmj.com
Sex cord stromal tumors (SCST) are rare cancers of the ovarian area in adults. They
constitute a heterogeneous group of tumors that develop from the sex cords and the ovarian …

[HTML][HTML] Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

AHM Reid, G Attard, DC Danila… - Journal of clinical …, 2010 - ncbi.nlm.nih.gov
Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate
Cancer With the CYP17 Inhibitor Abiraterone Acetate - PMC Back to Top Skip to main content …

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

SK Sandhu, K Papadopoulos, PC Fong… - Cancer chemotherapy …, 2013 - Springer
Purpose The CC-chemokine ligand 2 (CCL2) is highly expressed in various malignancies
and promotes carcinogenesis. Blocking CCL2 has preclinical antitumor activity. A phase 1 …

Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor

JS De Bono, G Attard, A Adjei, MN Pollak, PC Fong… - Clinical Cancer …, 2007 - AACR
Purpose: To detect insulin-like growth factor-IR (IGF-IR) on circulating tumor cells (CTC) as a
biomarker in the clinical development of a monoclonal human antibody, CP-751,871 …

Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised …

JA Ledermann, AM Oza, D Lorusso… - The Lancet …, 2020 - thelancet.com
Background In ARIEL3, rucaparib maintenance treatment significantly improved progression-
free survival versus placebo. Here, we report prespecified, investigator-assessed …

[HTML][HTML] Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

SJ Moschos, RJ Sullivan, WJ Hwu, RK Ramanathan… - JCI insight, 2018 - ncbi.nlm.nih.gov
BACKGROUND. Constitutive activation of ERK1/2 occurs in various cancers, and its
reactivation is a well-described resistance mechanism to MAPK inhibitors. ERK inhibitors …

[HTML][HTML] Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized …

ES Antonarakis, SH Park, JC Goh, SJ Shin… - Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
PURPOSE There is an unmet need for therapeutic options that prolong survival for patients
with heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC). The phase …